Wells Fargo Adjusts Price Target on Aeglea BioTherapeutics to 0.50 From 0.35, Maintains Equal-Weight Rating - Marketscreener.com

AGLEDelisted Stock  USD 0.59  0.01  1.72%   
About 54% of Aeglea Bio's shareholders are presently thinking to get in. The analysis of current outlook of investing in Aeglea Bio Therapeutics suggests that some traders are interested regarding Aeglea Bio's prospects. The current market sentiment, together with Aeglea Bio's historical and current headlines, can help investors time the market. In addition, many technical investors use Aeglea Bio Therapeutics stock news signals to limit their universe of possible portfolio assets.
  
Wells Fargo Adjusts Price Target on Aeglea BioTherapeutics to 0.50 From 0.35, Maintains Equal-Weight Rating Marketscreener.com

Read at news.google.com
Google News at Macroaxis
  

Aeglea Bio Fundamental Analysis

We analyze Aeglea Bio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Aeglea Bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Aeglea Bio based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Beta

Beta Comparative Analysis

Aeglea Bio is currently under evaluation in beta category among its peers. Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.

Aeglea Bio Therapeutics Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Aeglea Bio stock to make a market-neutral strategy. Peer analysis of Aeglea Bio could also be used in its relative valuation, which is a method of valuing Aeglea Bio by comparing valuation metrics with similar companies.

Peers

Aeglea Bio Related Equities

TILInstil Bio   16.79   
0%
100.0%
ASMBAssembly Biosciences   10.72   
0%
63.0%
ALRNAileron Therapeutics   7.03   
0%
41.0%
CTMXCytomX Therapeutics   6.25   
0%
37.0%
NUVBNuvation Bio   3.21   
0%
19.0%
XLOXilio Development   2.02   
0%
12.0%
SNTISenti Biosciences   1.42   
0%
8.0%
EWTXEdgewise Therapeutics   0.37   
0%
2.0%
IKNAIkena Oncology   1.17   
6.0%
0%
BNTCBenitec Biopharma   1.22   
7.0%
0%
ELYMEliem Therapeutics   1.30   
7.0%
0%
DSGNDesign Therapeutics   2.93   
17.0%
0%
CINGCingulate   3.67   
21.0%
0%
BPTHBio Path   3.75   
22.0%
0%
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.

Other Consideration for investing in Aeglea Stock

If you are still planning to invest in Aeglea Bio Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Aeglea Bio's history and understand the potential risks before investing.
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Global Correlations
Find global opportunities by holding instruments from different markets
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals